Back to Authors

Ballen, Karen

0000-0002-4872-2235

Mayo Clinic

Division of Hematology/Oncology, University of Virginia Health, Charlottesville, VA, United States.

Citations 1

Outcomes after 7/8 and
Jiménez, Antonio , Stanek, Joseph, Logan, Brent R, Leckrone, Erin , Stefanski, Heather E., Auletta, Jeffery J., Spellman, Stephen R., Malmberg, Craig, Askar, Medhat, Cusatis, Rachel , Shaffer, Brian C., Modi, Dipenkumar , Khimani, Farhad, Gooptu, Mahasweta, Bo‐Subait, Stephanie, Bolaños-Meade, Javier, Rao, Uttam, Milner, Jordan , Jamieson, Katarzyna , Carrum, George, Kosuri, Satyajit, Cook, Rachel J., Clara, Joseph , Loren, Alison W., Arai, Sally , Choi, Sung Won , Shaw, Bronwen E., Jimenez Jimenez, Antonio Martin , Cusatis, Rachel N , Hamadani, Mehdi , Maiers, Martin , Milner, Jordan , Abboud, Ramzi , Dholaria, Bhagirathbhai R , Hogan, William J , Reshef, Ran , Ballen, Karen , Larkin, Karilyn , Arai, Sally , Qayed, Muna , Choi, Sung Won , Broglie, Larisa A , Devine, Steven , Al Malki, Monzr M , Stanek, Joseph , Logan, Brent R. , Stefanski, Heather E. , Auletta, Jeffery J. , Spellman, Stephen R. , Malmberg, Craig, Askar, Medhat , Shaffer, Brian C. , Khimani, Farhad , Gooptu, Mahasweta , Hamadani, Mehdi , Maiers, Martin , Bolaños‐Meade, Javier , Dholaria, Bhagirathbhai , Hogan, William J. , Reshef, Ran , Cook, Rachel J. , Loren, Alison W. , Broglie, Larisa , Shaw, Bronwen E. , Devine, Steven M. , Malki, Monzr M. Al

Blood Advances | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021081 Get It

ACCESS is a prospective, multicenter phase II trial evaluating peripheral blood stem cell (PBSC) transplantation using 4-7/8 HLA-mismatched unrelated donors (MMUD) with post-transplant cyclophosphamide (PTCy), tacrolimus, and mycophenolate. Adults undergoing first HCT with myeloablative (MAC) or reduced-intensity/nonmyeloablative (RIC/NMA) conditioning were enrolled, with donors aged 18-35 years and matched at 4/8-7/8 HLA loci by high-resolution typing. This expanded analysis includes all enrolled adult PBSC recipients, including the protocol-specified RIC/NMA cohort expansion, to improve precision of outcome estimates and provide descriptive analyses by HLA match level. Among 268 adults, 183 received 7/8 and 85 received <7/8 MMUD grafts; 82.4% of the <7/8 cohort received 6/8 grafts. Median follow-up among survivors was 11.9 months. At 1-year, overall survival was 78.6% (95% CI, 71.9-83.9) in the 7/8 cohort and 85.6% (95% CI, 76.0-91.5) in the <7/8 cohort. One-year relapse, non-relapse mortality, and GVHD-free relapse-free survival were 17.1%, 13.7%, and 51.1% versus 22.8%, 8.4%, and 54.6%, respectively. The cumulative incidence of grade II-IV and grade III-IV acute GVHD by day 100 was 36.6% and 7.7% in the 7/8 cohort versus 28.3% and 5.9% in the <7/8 cohort. Moderate-to-severe chronic GVHD at 1 year was 11.3% versus 7.7%, respectively. Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging. Because donor match level was not prospectively assigned and between-group comparisons were exploratory, these findings are descriptive and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation. (Registered as NCT04904588 at CT.gov)